Emerging Pharmacological Therapy in Patients with Advanced Occlusive Peripheral Vascular Disease

Schroll M Munck O. Estimation of peripheral atherosclerotic disease by ankle blood pressure measurements in a population study of 60 year old men and women. J Chron Dis 1982; 34: 261–69.

Criqui MH Fronek A Barrett-Connor E Klauber MR Gabriel S Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510–15.

Hale WE Marks RG May FE Moore MT Stewart RB . Epidemiology of intermittent claudication: Evaluation of risk factors. Age Aging 1988; 17: 57–60.

Agner E. Natural history of angina pectoris, possible intermittent claudication and intermittent claudication during the eight decade. Acta Med Scand 1981; 201: 271–76.

Kannel WB McGee DL . Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985; 33: 13–18.

Dormandy J Mahir M Ascady G Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg 1989; 30: 50–57.

Kannel WB Shurtleff D. The Framingham Study. Cigarettes and the development of intermittent claudication. Geriatrics 1973; 28: 61–68.

Kozak GP Rowbotham JL . Diabetic foot disease: A major problem. Kozak GP eds. Management of diabetic foot problems. Philadelphia: WB Saunders, 1984.

Friedman SA Hilling HE Roberts B. Etiologic factors in aortoiliac and femoropopliteal vascular disease. N Engl J Med 1964; 271: 1382–85.

Haycraft JB . Uber die Einwirkung eines Sekrates des officinellen Blutegels auf die Gerinnbarkeit des Blutes. Arch Exp Pathol Pharmakol 1884; 18: 209.

Markwardt F. Die Isoliegrung und chemische Charakterisisierung des Hirudins. Hoppe-Seylers Z Physiol Chem 1957; 308: 147–56.

Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 1970; 19: 924–32.

Grossenbacher H Auden J Bill K Liersch M Marki W. Isolation and characterization of recombinant desulphatohirudin from eyast: A highly selective thrombin inhibitor. Thromb Haemost 1987; Suppl VII: 34.

Meyhack B Heim J Rink H Zimmerman W Marki W. Desulphatohirudin, a specific thrombin inhibitor: Expression and secretion in yeast. Thromb Haemost 1987; Suppl VII: 33.

Zoldelyi P Webster MWI Fuster V Recombinant hirudin in patients with chronic stable coronary artery disease, safety, half-life and effect on coagulation parameters. Circulation 1993; 88 (Part I): 2015–22.

Verstraete M Nurmohamed M Kienast M Biologic effects of recombinant hirudin (CGP39393) in human volunteers. J Am Coll Cardiol 1993; 22: 1080–92.

Cannon CP Maraganore JM Loscalzo J Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993; 71: 778–82.

Skrzypczak-Jankum E Carperos VE Ravichandran KG Structure of the hirugen and hirulog-1 complexes of alpha-thrombin. J Mol Biol 1992; 221: 1379–93.

Bourdon P Jablonski J Chao BH Maragnore JM . Structure–function relationship of hirulog peptide interactions with thrombin. FEBS Lett 1991; 294: 163–66.

Fox I Dawson A Loynds P Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 2: 157–63.

Lidon RM Theroux P Juneau M Adelman B Maraganore J. Initial experience with direct antithrombin hirulog, in unstable angina. Circulation 1993; 88: (Part I): 1495–501.

Topol EJ Bonan R Jewitt D Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622–29.

Waxman L Smith DE Arcuri KE Vlasuk GP . Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593–96.

Schaffer LW Davison JT Vlasuk GP Siegl PKS . Antithrombotic efficacy of recombinant tick anticoagulant peptide. Circulation 1991; 84: 1741–48.

Dunwiddie CT Nutt EM Vlasuk GP Siegal PKS Schaffer LW . Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistatin following subcutaneous administration in the Rhesus monkey. Thromb Haemost 1992; 3: 371–76.

Warn-Cramer BJ Rapaport SI . Studies the factor Xa/phospholipid-induced intravascular coagulation in rabbits. Arterioscler Thromb 1993; 13: 1551–57.

Haskel EJ Torr SR Day KC Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821–27.

Ruf W Edgington TS . An anti-tissue factor monoclonal antibody which inhibits TFVIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991; 5: 529–33.

Thery C Simonnearu G Meyer G. Randomized trial of subcutaneous low molecular weight heparin VY216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation 1992; 85: 1380–89.

Hull RD Raskob GE Pineo GF Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975–82.

Albada J Nieuwenhuis HK Sixma JJ . Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin). Circulation 1989; 80: 935–40.

Harker LA Malpass TW Branson HE Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective α-granule release. Blood 1980; 56: 824–34.

Strony J Phillips M Brands D Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation 1990; 81: 1106–14.

Yasuda T Gold HK Leinback RC Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990; 16: 1738–35.

Musial J Niewiarowski S Ruchinski B Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins: RDG-containing peptides from viper venoms. Circulation 1990; 82: 261–73.

Saltiel R Ward A. Ticlopidine: A review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–62.

Fitzgerald GA Reilly LA Pederson AK . The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72: 1194–201.

Mullane KM Foinabaio D. Thromboxane synthestase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism. Circ Res 1988; 62: 668–78.

Saussy DL Jr Mais De Knapp DR Halushka PV . Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation 1985; 72: 1202–207.

Clubb FJ Schmitz JM Butler MM Effect of dietary omega-3 fatty acid on serum lipids, platelet function, and atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1989; 9: 529–37.

Spector AA Kaduce TL Figard PH Eicosapentaenoic and prostacyclin production by the cultured human endothelial cells. J Lipid Res 1983; 24: 1595–604.

Needleman P Sprecher H Whitaker MO Wyche A. Mechanism underlying the inhibition of platelet aggregation by eicosapentaenoic acid and its metabolites. In: Samuelsson B Ramwell PW Paoletti R eds. Advances in prostaglandin and thromboxane research. New York: Raven Press, 1980.

Fischer-Dzoga K Kuo YF Wissler RW . The proliferation effect of platelet and hyperlipidemic serum on stationary primary cultures. Atherosclerosis 1983; 47: 35–45.

Tiell ML Sussman II Gordon PB . Suppression of fibroblast proliferation in vitro and myointimal hyperplasia in vivo by the trazolopyrimidine, Trapidil. Artery 1983; 12: 33–50.

Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–33.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Br Med J 1994; 308: 81–106.